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OBJECTIVES: The purpose of this project was to assess the
prevalence and risk factors for diarrhea at a large tertiary care
medical center. METHODS: Prospective cross-sectional study
conducted on December 13, 2004 in a 600-bed tertiary care
medical center. All patients hospitalized for greater than 24-
hours on the study day were interviewed. Patients were asked if
they were experiencing diarrhea (deﬁned as passing of two or
more unformed stools in the past 24-hours.) All patients report-
ing diarrhea were tested for Clostridium difﬁcile. Patient demo-
graphics, and use of antibiotics, tube feeds, GI motility agents,
steroids, chemotherapy proton pump inhibitors were collected
for every patient. Chi-square analysis was used to determine risk
factors for diarrhea. RESULTS: A total of 485 patients were
interviewed for the study, of which 60 (12.3%) patients reported
diarrhea. The risk factors for diarrhea include Clostridium difﬁ-
cile infection (OR 15.1, p < 0.0001), hospitalization duration 
(p < 0.0001), current use of antibiotics (OR 1.95, p < 0.0166),
and tube feeds (OR 3.34, p < 0.0018). Prevalence of diarrhea
increased with longer duration of hospitalization (p = 0.03).
CONCLUSION: Twelve percent of hospitalized patients experi-
enced diarrhea in our study. Common risk factors for diarrhea
included C. difﬁcile infection, current use of antibiotics, tube
feeds, or longer hospitalizations.
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OBJECTIVE: To develop a budget impact model that assesses
the economic impact of adding tegaserod for the management of
irritable bowel syndrome with constipation to a managed care
organization’s (MCO) formulary. METHODS: The model esti-
mates per patient and per-member per-month (PMPM) economic
impact of two patient subgroups six-months prior to and six-
months after the initiation of tegaserod. The incremental budget
impact of tegaserod was then calculated by subtracting the prior
period costs from the post period costs. The two patient sub-
groups were 1) females with an IBS diagnosis (FIBS); and 2)
males and females with other GI diagnosis (GID). Resource uti-
lization data were based on a retrospective, longitudinal study
of 3365 tegaserod users from a large, geographically-diverse
MCO utilizing medical and pharmacy administrative claims
data. We used prevalence and tegaserod treatment rates observed
from the aforementioned MCO. Sensitivity analyses were per-
formed by varying several model inputs parameters. RESULTS:
The base-case model resulted in an incremental PMPM budget
impact associated with the use of tegaserod of $0.01. Total 
per-patient budget impact (for all resources, including tegaserod)
for a six-month period was $274.34 for FIBS and $301.84 
for GID. Overall, 25.9% (29.0% for FIBS and 21.9% for GID)
of the cost of tegaserod was offset by decreases in resource uti-
lization. Key drivers of post-tegaserod reductions in resource
costs were hospital stays, abdominal and pelvic CAT scans,
colonoscopies (for FIBS), and outpatient ofﬁce consultations and
emergency room visits (for GID). CONCLUSIONS: Tegaserod
therapy can decrease GI-related resource use, resulting in a sig-
niﬁcant cost-offset percentage. When the associated budget
impact of adding tegaserod to formulary is absorbed across 
an entire MCO population, the PMPM impact of tegaserod is
small.
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OBJECTIVES: Short bowel syndrome (SBS) results from exten-
sive surgical removal of portions of the small intestine, and leads
to serious morbidity and shortened life expectancy. A recent trial
showed that use of somatropin [rDNA origin] for injection
(rhGH) signiﬁcantly reduces the need for standard treatments
such as parenteral nutrition (PN), which signiﬁcantly impair
quality of life. This study sought to evaluate the economic impact
of this new treatment. METHODS: A discrete event simula-
tion was developed to compare a regimen of daily rhGH for 
four weeks with PN alone in the management of patients with
SBS. Risks of treatment- and disease-related complications and
resource use were modeled in two identical cohorts of 1000
patients for two years. Rates of disease-related events (e.g.,
biliary problems), including age-dependent mortality, were
assumed to be the same across strategies. Risk functions for each
strategy were estimated from the literature and one randomized
clinical trial. Direct medical costs were obtained from Medicaid
and the literature. Sensitivity analyses were conducted on key
parameters. Direct medical costs are reported in US$2004. All
outcomes were discounted at 3%/yr. RESULTS: Overall, 96.0%
of patients receiving rhGH reduced or eliminated PN use within
six weeks of initiating the regimen; one-third weaned completely;
and PN use decreased 2.8 days. PN was estimated to cost
$118,099 in year one and $132,935 in year two, totaling
$251,033 vs rhGH cost of $84,309, including $17,459 for treat-
ment, in year one, a savings of $33,790 per patient; over two
years $165,559, for a total savings of $85,474. Cost neutrality
is achieved within eight months. Sensitivity analyses showed no
signiﬁcant change in results. CONCLUSIONS: The reduction of
PN use or complete weaning in the vast majority of patients with
rhGH results in a substantial savings and improvement in quality
of life—a dominant strategy.
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Although hepatitis A and B vaccinations are recommended for
patients with chronic hepatitis C virus (HCV), the ideal vacci-
nation strategy is not determined. OBJECTIVE: To model the
cost-effectiveness of two strategies of vaccinating patients with
HCV infection against hepatitis A (HAV) and hepatitis B (HBV)
viruses. The strategies evaluated were: universal vaccination with
the combined HAV and HBV vaccine, and selective vaccination
based on immunity by blood testing. METHODS: A decision
tree computer model was constructed to compare the cost-
effectiveness of the two vaccination strategies from the New
Mexico Veterans Affairs Health Care System (NMHAHCS) per-
spective. A retrospective review of all HCV patients (2542 sub-
jects) at the NMVAHCS was performed to extract prevalence of
immunity to HAV and HBV, and prevalence of decompensated
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liver disease. Literature review was performed to obtain other
probabilities for the model. The effectiveness measure was the
number of patients immune to both HAV and HBV. RESULTS:
The selective strategy was less costly but less effective with a 
cost-effectiveness ratio of $105 per patient immune to HAV&
HBV. The universal strategy was more effective but more 
expensive with a cost-effectiveness ratio of $112 per patient
immune to HAV& HBV. Compared with the selective strategy,
universal strategy was associated with an incremental cost-
effectiveness (ICE) ratio of $154 per additional patient immune
to HAV and HBV. The universal strategy would become more
cost-effective if the cost of combined vaccine reduces by >9.7%
to <$0.75, if the cost of HBV vaccine increases by >25% to
>$34.50, if the cost of blood tests for immunity increases by
>23% to >$25.25, or if the prevalence of anti-HBs decreases 
to <24%. CONCLUSIONS: The selective vaccination strategy
for HAV and HBV in our sample of patients with HCV is more
cost-effective. However, the ICE for the universal strategy is
minimal.
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Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment
option for patients infected with chronic hepatitis B (CHB),
offers improved efﬁcacy with a deﬁned treatment duration 
compared with lamivudine (LAM), but at a higher cost. 
OBJECTIVE: To assess the clinical outcomes, costs and cost-
effectiveness of PEGASYS for the treatment of patients with
HBeAg-negative CHB, compared to LAM treatment for one-year
and four-years. METHODS: A cost-effectiveness analysis from
the UK National Health Service (NHS) perspective using a state-
transition Markov model simulating the natural history of
HBeAg-negative CHB. Efﬁcacy data were obtained from a
recent, randomized clinical trial comparing PEGASYS and LMV
in patients with HBeAg-negative CHB. Patients: Hypothetical
cohort of 40-year old patients with HBeAg-negative CHB. Inter-
ventions: PEGASYS and LAM monotherapy. Measurements: Life
expectancy, quality-adjusted life expectancy, lifetime costs, and
incremental cost-effectiveness ratios (ICERs). RESULTS: Forty-
eight week treatment with PEGASYS compared to LAM resulted
in higher total costs, but greater quality-adjusted life expectancy,
yielding an ICER of £5047/quality-adjusted life year (QALY)
gained. Although there is uncertainty associated with the prog-
nosis of HBeAg-negative CHB, the ICER did not exceed
£10,000/QALY gained despite variation in each parameter used
in the analysis. In the analysis comparing 48-week treatment
with PEGASYS to 208-week treatment with LAM, the ICER was
£2767/QALY gained. CONCLUSIONS: Short-term treatment
with PEGASYS compared to either short-term or long-term
LAM treatment in CHB patients who are HBeAg-negative
appears to offer life expectancy beneﬁts at a cost-effectiveness
ratio comparable to other currently reimbursed pharmaceutical
interventions.
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OBJECTIVE: Evaluate utilization and expenditure for treatment
of gastrointestinal infection with Helicobacter pylori (H. pylori)
by different durations of treatment. METHODS: Retrospective
analysis of pharmacy and outpatient procedure claims between
January 1, 2000 and December 31, 2002 in the MarketScan®
Commercial Claims and Encounters, Medicare Coordination of
Beneﬁts, and January 1, 1999 and December 31, 2001 in Multi-
State Medicaid databases. Patients were required to have one
claim for any proton pump inhibitor (esomeprazole, lansopra-
zole, omeprazole, pantoprazole, rabeprazole) and an antibiotic
combination of amoxicillin/clarithromycin (AC) or metronida-
zole/tetracycline (MT). Treatment patterns were evaluated along
with re-treatment rates (regimen effectiveness), testing rates, and
pharmaceutical expenditures. RESULTS: In total, 10,203
patients were identiﬁed; the average patient age was 52.8 years,
the majority of patients were female, 41.6% had privately
funded insurance and 58.4% had publicly funded insurance. The
majority of patients were naïve to H. pylori eradication therapy
over the 12 months prior to initial therapy and 92.6% of patients
received AC as their antibiotic combination. Fourteen-day triple
therapy (PPI + two antibiotics) was prescribed for majority
(80%) of patients regardless of H. pylori eradication therapy
treatment history. Re-treatment rates did not vary signiﬁcantly
among different triple therapy treatment regimen durations:
7.8% for seven day, 7.6% for ten day, and 7.9% for 14 day reg-
imens. However, the cost of initial treatment for the different
treatment durations varied widely, $120.82 for seven day regi-
mens, $178.79 for ten day regimens, and $294.49 for 14 day
regimens. CONCLUSION: This study found signiﬁcant differ-
ences in treatment costs by duration of therapy despite similar
re-treatment rates among different lengths (seven day vs. 14 day)
of H. pylori triple therapy regimens. There are potential eco-
nomic beneﬁts realized in shorter duration of treatment, as mea-
sured by the direct expenditures on the medications themselves,
and associated re-treatment and testing expenditures.
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OBJECTIVE: Crohn’s disease (aka: inﬂammatory bowel disease,
regional enteritis) is a chronic autoimmune disorder that can
occur at any age. This analysis examined use and cost of hospi-
talizations, observation unit (OU) stays and emergency depart-
ment (ED) visits during a one-year period by patients with
Crohn’s disease. METHODS: Using 2001–2002 Massachusetts
ED, OU and inpatient data, a cohort was identiﬁed by personal
identiﬁers and ICD-9 principal diagnosis codes (555.0–555.9).
An encounter proﬁle was established for each patient starting
with the ﬁrst stay or visit at any hospital, ED or OU in Massa-
chusetts in 2001. From that index encounter, each contact for
regional enteritis was tracked for 12 months for that patient.
Cost estimates, reported in 2004 USD, include accommodations
and ancillary services. Charges were adjusted using a 0.55 cost-
to-charge ratio and appropriate inﬂation indices. RESULTS: A
